Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
Total Valuation
NewAmsterdam Pharma Company has a market cap or net worth of $4.00B. The enterprise value is $3.57B.
Market Cap$4.00B
Enterprise Value$3.57B
Share Statistics
NewAmsterdam Pharma Company has 113,390,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113,390,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NewAmsterdam Pharma Company’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)0.00
Return on Assets (ROA)0.00
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee330.93K
Profits Per Employee0.00
Employee Count68
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NewAmsterdam Pharma Company is ―. NewAmsterdam Pharma Company’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value0.00
Price to FCF0.00
Price to Operating Cash Flow-29.47
PEG Ratio0.00
Income Statement
In the last 12 months, NewAmsterdam Pharma Company had revenue of 22.50M and earned 0.00 in profits. Earnings per share was -1.72.
Revenue22.50M
Gross Profit0.00
Operating Income0.00
Pretax Income0.00
Net Income0.00
EBITDA0.00
Earnings Per Share (EPS)-1.72
Cash Flow
In the last 12 months, operating cash flow was -144.39M and capital expenditures -149.00K, giving a free cash flow of -144.54M billion.
Operating Cash Flow-144.39M
Free Cash Flow-144.54M
Free Cash Flow per Share-1.27
Dividends & Yields
NewAmsterdam Pharma Company pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.19
52-Week Price Change88.21%
50-Day Moving Average34.12
200-Day Moving Average28.46
Relative Strength Index (RSI)59.84
Average Volume (3m)651.46K
Important Dates
NewAmsterdam Pharma Company upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateFeb 18, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
NewAmsterdam Pharma Company as a current ratio of 7.88, with Debt / Equity ratio of 0.03%
Current Ratio7.88
Quick Ratio7.88
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, NewAmsterdam Pharma Company has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NewAmsterdam Pharma Company EV to EBITDA ratio is 0.00, with an EV/FCF ratio of 3.31.
EV to Sales-21.77
EV to EBITDA0.00
EV to Free Cash Flow3.31
EV to Operating Cash Flow3.31
Balance Sheet
NewAmsterdam Pharma Company has $702.95M in cash and marketable securities with $266.00K in debt, giving a net cash position of $702.68M billion.
Cash & Marketable Securities$702.95M
Total Debt$266.00K
Net Cash$702.68M
Net Cash Per Share$6.20
Tangible Book Value Per Share$0.00
Margins
Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin100.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for NewAmsterdam Pharma Company is $47.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$47.56
Price Target Upside33.00% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast―
EPS Growth Forecast―